PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

  1. Quiñonero, F.
  2. Mesas, C.
  3. Muñoz-Gámez, J.A.
  4. Jiménez-Luna, C.
  5. Perazzoli, G.
  6. Prados, J.
  7. Melguizo, C.
  8. Ortiz, R.
Aldizkaria:
Biomedicine and Pharmacotherapy

ISSN: 1950-6007,  0753-3322

Argitalpen urtea: 2022

Alea: 155

Mota: Artikulua

DOI: 10.1016/J.BIOPHA.2022.113669 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus